Evoke Pharma Announces a Fireside Chat with Key Opinion Leaders on the Treatment of Gastroparesis
|Details of the fireside chat are below:|
In addition, investors are encouraged to email firstname.lastname@example.org prior to the event with questions they may have for
Evoke is a specialty pharmaceutical company focused primarily on the commercialization and development of drugs to treat GI disorders and diseases. The Company developed GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in
Source: Evoke Pharma, Inc.